Key facts
- This page summarizes Robert E. Hoffman's Form 4 filing for TuHURA Biosciences, Inc./NV (HURA).
- 1 reported transaction and 2 derivative rows are listed below.
- Accepted by SEC: 17 Feb 2026, 16:09.
Robert E. Hoffman - 12 Feb 2026 Form 4 Insider Report for TuHURA Biosciences, Inc./NV (HURA)
- Reporting relationship
- Director
- Issuer ticker
- HURA
- Reported as of
- 12 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Feb 2026, 16:09:41 UTC
- Prior SEC filing
- 12 Jun 2025
- Next SEC filing
- 24 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert E. Hoffman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Hoffman filed Form 4 for TuHURA Biosciences, Inc./NV (HURA) on 17 Feb 2026.
Change
- Previous filing in this sequence was filed on 12 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001166288
Primary reporting owner
Hoffman Robert E.
- Relationship
- Director
- Address
- 10500 UNIVERSITY CENTER DRIVE, SUITE 110, TAMPA
- Signature
- /s/ Robert E. Hoffman
- Signature date
- 17 Feb 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HURA
transaction
Derivative
Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +156,240
- Change %
- Price
- $0.000000
- Shares after
- 156,240
- Date
- 12 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 156,240
- Exercise price
- $1.29
- Footnotes
- F1
HURA
holding
Derivative
Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 51,275
- Date
- 12 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 51,275
- Exercise price
- $4.11
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.
Footnote F2
Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.